查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879318

傳染病治療市場－全球產業規模、佔有率、趨勢、機會和預測，依疾病類型、最終用途、地區和競爭格局分類，2020-2030年預測

Infectious Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By End Use, By Region, and By Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球傳染病治療市場規模為676.4億美元，預計到2030年將以7.74%的複合年成長率成長至1058億美元。全球傳染病治療市場涵蓋用於預防、治療和控制由致病微生物（包括細菌、病毒、真菌和寄生蟲）引起的疾病的藥物和醫療干預措施。推動市場擴張的關鍵因素包括全球傳染病流行率的上升、抗菌素抗藥性持續存在的挑戰，以及為滿足未被滿足的醫療需求而不斷增加的研發投入。診斷技術的不斷進步，使得疾病的早期和精準識別成為可能，也進一步促進了市場成長。

市場概覽
預測期 2026-2030
2024年市場規模 676.4億美元
2030年市場規模 1058億美元
2025-2030年複合年成長率 7.74%
成長最快的細分市場 醫院
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球傳染病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（愛滋病、肝炎、流感、結核病、瘧疾、人類乳突病毒、其他）
    • 依最終用途（醫院、診所、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美傳染病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲傳染病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區傳染病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲傳染病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲傳染病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球傳染病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Novartis AG
  • Gilead Sciences Inc
  • GSK PLC
  • Johnson & Johnson Innovative Medicine
  • F Hoffmann-La Roche AG
  • BioCryst Pharmaceuticals Inc
  • Merck & Co Inc
  • Boehringer Ingelheim International GmbH

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20908

The Global Infectious Disease Therapeutics Market, valued at USD 67.64 Billion in 2024, is projected to experience a CAGR of 7.74% to reach USD 105.80 Billion by 2030. The Global Infectious Disease Therapeutics Market encompasses pharmaceutical agents and medical interventions designed for the prevention, treatment, and management of illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. Key drivers supporting market expansion include the increasing global prevalence of infectious diseases, the persistent challenge of antimicrobial resistance, and growing investments in research and development to address unmet medical needs. Further impetus comes from continuous advancements in diagnostic technologies enabling earlier and more precise disease identification.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 67.64 Billion
Market Size 2030USD 105.80 Billion
CAGR 2025-20307.74%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

The increasing global burden of infectious diseases fundamentally drives market expansion, creating persistent and widespread demand for effective treatments and preventative measures. Diseases like tuberculosis and malaria continue to exact a significant toll on global health, necessitating ongoing research and development into novel pharmacological agents and improved therapeutic strategies. The sheer scale of these challenges ensures a consistent market for diagnostics, drugs, and vaccines, as healthcare systems grapple with endemic infections and outbreaks. According to the World Health Organization, in its Global Tuberculosis Report 2023, an estimated 10.6 million people fell ill with tuberculosis worldwide in 2022, underscoring the critical need for continued therapeutic interventions. This sustained disease pressure compels pharmaceutical companies to invest in developing new therapies to address unmet medical needs.

Key Market Challenges

A significant challenge impeding the growth of the Global Infectious Disease Therapeutics Market is the substantial costs associated with drug discovery and development. Bringing new pharmaceutical agents from initial research to market approval demands extensive financial outlays for preclinical studies, multiple phases of clinical trials, and manufacturing infrastructure. This immense capital requirement significantly raises the barrier to entry for innovators and imposes considerable financial risk on companies, influencing strategic decisions about which therapeutic areas to prioritize.

Key Market Trends

The application of Artificial Intelligence (AI) in drug discovery is significantly reshaping the development landscape for infectious disease therapeutics. AI algorithms are increasingly employed to accelerate the identification of novel drug targets, optimize compound synthesis, and predict drug efficacy and toxicity with greater precision and speed, thereby reducing the time and cost associated with traditional drug development. This technological integration is poised to streamline the discovery of urgently needed treatments for evolving pathogens. According to a survey from Rackspace Technology and Dell/VMware, conducted in October 2023, two out of three pharmaceutical companies (67%) planned to increase their investment in information technology, including artificial intelligence, over the subsequent 12 months. This substantial industry-wide commitment to AI is expected to catalyze innovation across all therapeutic areas, including infectious diseases, by enhancing the efficiency of research and development pipelines.

Key Market Players

  • Novartis AG
  • Gilead Sciences Inc
  • GSK PLC
  • Johnson & Johnson Innovative Medicine
  • F Hoffmann-La Roche AG
  • BioCryst Pharmaceuticals Inc
  • Merck & Co Inc
  • Boehringer Ingelheim International GmbH

Report Scope:

In this report, the Global Infectious Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Therapeutics Market, By Disease Type:

  • HIV
  • Hepatitis
  • Influenza
  • TB
  • Malaria
  • HPV
  • Others

Infectious Disease Therapeutics Market, By End Use:

  • Hospitals
  • Clinics
  • Others

Infectious Disease Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infectious Disease Therapeutics Market.

Available Customizations:

Global Infectious Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others)
    • 5.2.2. By End Use (Hospitals, Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Infectious Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Infectious Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Infectious Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Infectious Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By End Use

7. Europe Infectious Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Infectious Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Infectious Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Infectious Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Infectious Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Infectious Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By End Use

8. Asia Pacific Infectious Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Infectious Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Infectious Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Infectious Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Infectious Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Infectious Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Infectious Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Infectious Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Infectious Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Infectious Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By End Use

10. South America Infectious Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Infectious Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Infectious Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Infectious Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Infectious Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences Inc
  • 15.3. GSK PLC
  • 15.4. Johnson & Johnson Innovative Medicine
  • 15.5. F Hoffmann-La Roche AG
  • 15.6. BioCryst Pharmaceuticals Inc
  • 15.7. Merck & Co Inc
  • 15.8. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer